Please login to the form below

Not currently logged in
Email:
Password:

niraparib

This page shows the latest niraparib news and features for those working in and with pharma, biotech and healthcare.

CHMP backs AZ’s Lynparza for ovarian cancer maintenance

CHMP backs AZ’s Lynparza for ovarian cancer maintenance

in the face of competition from newer market entrants Rubraca (rucaparib) from Clovis Oncology and Johnson &Johnson/Tesaro’s Zejula (niraparib).

Latest news

More from news
Approximately 3 fully matching, plus 19 partially matching documents found.

Latest Intelligence

  • Deal Watch April 2016 Deal Watch April 2016

    Licensing one indication for a new product is unusual not least of all because of potential pricing issues if niraparib is launched by different companies at different prices. ... 500. Tesaro (US). Janssen (US). License and collaboration. Niraparib PARP

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics